欢迎访问《现代生物医学进展》编辑部！

目的：利用溶瘤腺病毒CNHK500 体外转染内皮祖细胞，评估其在体外对肺腺癌细胞的特异性杀伤作用。方法：通过溶瘤腺病毒CNHK500转染内皮祖细胞，构建携带CNHK500 的内皮祖细胞，并将内皮祖细胞和CNHK500 分为三组，即CNHK500 组，转染CNHK500 的内皮祖细胞组和内皮祖细胞组，分别感染肺腺腺癌细胞A549，用MTT 法检测不同肺腺癌细胞A549 的生长抑制情况。结果：成功的分离并培养、鉴定内皮祖细胞，并完成CNHK500 对内皮祖细胞的转染，CNHK500 滴度为2.0× 107 pfu/mL，其中CNHK500 组肺腺癌细胞A549 的存活率为（75.54± 5.46）%，转染CNHK500 的EPCs 组肺腺癌细胞A549 的存活率为（80.81± 3.69）%，EPCs 组肺腺癌细胞A549 的存活率为（98.13± 2.98）%。结论：本实验首次成功的将CNHK500 转染内皮祖细胞，并应用于肺腺癌细胞的生长抑制中，这将有助于为肺腺癌的生物治疗提供一个崭新的策略。

英文摘要:

Objective:By means of transfecting oncolytic adenovirus CNHK500 into endothelial progenitor cells in vitro, its effect of inhibiting the growth of lung adenocarcinoma cells can be observed and evaluated.Methods:The endothelial progenitor cells loaded with CNHK500 were acquired through the transfection of EPCs by CNHK500, and then were divided into three groups, CNHK500, endothelial progenitor cells transfected by CNHK500 and endothelial progenitor cells. MTT assay was performed to determine the inhibitory effect on lung adenocarcinoma cells.Results:Endothelial progenitor cells were isolated, cultured, identified and transfected by CNHK500 successfully, and CNHK500 titer was 2× 107 pfu/mL, in which, lung adenocarcinoma cells A549 survival rate of CNHK500 group was (75.54± 5.46)%, lung adenocarcinoma cells A549 survival rate of EPCs transfected by CNHK500 group was (80.81± 3.69)%, lung adenocarcinoma cells A549 survival rate of EPCs group was (98.13± 2.98)%.Conclusion:In this study, CNHK500 was successfully applied to kill lung adenocarcinoma cells by using endothelial progenitor cells as the carrier, which could provide a new strategy for targeted therapy of lung adenocarcinoma cells.

查看全文查看/发表评论下载PDF阅读器

关闭